Express News | Venus Medtech Venusp-Valve Completed First Implantation in Ide Pivotal Clinical Study in U.S.
Venus Medtech (Hangzhou) Implants First Patient With VenusP-Valve in US Clinical Study
Venus Medtech (Hangzhou) (HKG:2500) said it successfully implanted the first patient with the self-developed transcatheter pulmonary valve replacement (TPVR) system VenusP-Valve as part of a clinical
QiMing Medical (02500): The company's self-developed PROTEUS IDE key clinical trial was recently launched and the first patient was implanted.
Kingold News | Qiming Medical (02500) announced that the company's self-developed transcatheter pulmonary valve replacement (TPVR) system, VenusP-Valve, has officially launched a critical clinical trial (PROTEUS IDE) in USA and successfully completed the first patient implantation. This marks a significant international clinical breakthrough for VenusP-Valve, following the CE MDR certification it obtained in Europe in April 2022. The start of this clinical trial means that VenusP-Valve is expected to become the leading Chinese technology approved on a global scale.
The first critical clinical patient of VENUSP-VALVE implantation in the United States IDE was successful in Qiming Medical -B (02500).
Qiming Medical -B (02500) released an announcement that the company's independently developed transcatheter pulmonary valve replacement (TPV)...
Qiming Medical-B (02500.HK): All major aspects of the Group's business operations continue to be suspended as usual
Gelonghui, May 23 | Qiming Medical-B (02500.HK) announced that the Group is mainly engaged in innovative medical device business integrating R&D, clinical development, production and commercialization. As far as the directors are aware, as of the date of this announcement, the Group's business operations were carried out as usual in all major aspects. Based on its assessment, the Board considers that the unauthorized transaction did not have any significant adverse effect on the Group's business operations. Continued suspension of trading.
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
Venus Medtech Board Receives Internal Control Review Report From Consultant
Venus Medtech (Hangzhou) (HKG:2500) board received a thorough internal control review report from Deloitte Enterprise Consulting (Shanghai), the review consultant, according to a Monday filing on the
Qiming Medical-B (02500) completed internal control review
Qiming Medical-B (02500) issued an announcement. On the date of this announcement, all the remedies recommended by the internal control consultant have been...
Between the suspension of trading and the resumption of trading, what step did Qiming Medical-B (02500) take on its path back?
Up to now, only 80 million of the remaining funds transferred by former executives in violation of regulations have not been repaid, and it is expected that all of them will be repaid by September 30, 2024.
啓明醫療-B:2023年度報告
Kai Ming Medical-B (02500.HK): Further updates on unauthorized loans and pledge deposits continue to be suspended
Gelonghui, April 16, 丨 Qiming Medical-B (02500.HK) issued an announcement. As of the date of this announcement, an unauthorized pledge deposit of RMB 100 million provided by Hangzhou Qiyi (a wholly-owned subsidiary of the company) to guarantee the Hangzhou Kuntai loan (due to expire on April 14, 2024) has been released from the relevant bank and further withdrawn by the company from the bank. Furthermore, as of the date of this announcement, Hangzhou Qiyi has received interest income of RMB 2,0506 million on these deposits. On the date of this announcement, the Group's previous pledges were made to guarantee the loan and on the date of the forensic investigation announcement
Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21%
Venus Medtech (Hangzhou) (HKG:2500) narrowed its loss attributable to owners of the parent to 720.9 million yuan in 2023, from 1.06 billion yuan in the year-ago period, according to a March 28 filing
Qiming Medical-B (02500) released annual results, gross profit of 389 million yuan, a year-on-year increase of 23.95%
Qiming Medical-B (02500) announced its annual results for the year ended December 31, 2023. The group...
VENUS MEDTECH-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
VENUS MEDTECH-B: DATE OF BOARD MEETING AND CONTINUED SUSPENSION OF TRADING
Zhongtai Securities: Edward Evoque received FDA approval and continues to be optimistic about the commercialization prospects of tricuspid valve intervention
Recently, Edward Life Sciences announced that its tricuspid valve product Evoque has been approved by the FDA for marketing. This is the first FDA-approved tricuspid valve replacement product.
Kai Ming Medical-B received additional guidance from the Stock Exchange to continue suspending trading
Kai Ming Medical-B (02500) announced that the company received a letter from the Stock Exchange on February 9, 2024, according to which the Exchange issued additional guidance on the resumption of trading to the company after the death of Mr. Lau Wan-yee: to re-comply with the requirements of section 3.10 (1), section 3.10A, section 3.21 and section 3.27A of the listing rules relating to the composition and chairmanship of the board of directors and its board committee (if applicable). Trading of the company's shares continues to be suspended.
Kai Ming Medical-B (02500) received additional guidance from the Exchange to resume trading and continued to be suspended
According to Zhitong Financial App News, Qiming Medical-B (02500) announced that the company received a letter from the Stock Exchange on February 9, 2024. According to this, the Stock Exchange issued additional guidance on resuming trading to the company after the death of Mr. Lau Yun-yi: re-complying with the requirements of section 3.10 (1), section 3.10A, section 3.21 and section 3.27A of the listing rules relating to the composition and chairman of the board committee (if applicable). Trading of the company's shares continues to be suspended.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Qiming Medical-B (02500.HK): Wang Fei appointed as Chief Financial Officer
Gelonghui January 4 | Qiming Medical-B (02500.HK) issued an announcement. Wang Fei has been appointed as Chief Financial Officer with effect from January 4, 2024. Trading of the Company's shares has been suspended on the Stock Exchange since 9:00 a.m. on November 23, 2023, and will continue to be suspended until further notice.
No Data